Allergan (AGN) says Darpin data does not support Phase 3 trials.

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 6/26/2026

1. ON
2. SYNA
3. SPY
4. DRI
5. MU

6. FDXF
7. MKC
8. NKE
9. AMAT
10. TCOM

May 1, 2013 11:08 AM EDT

Price: $193.02 --0%

Overall Analyst Rating:
SELL (= Flat)

Dividend Yield: 1.6%

UPDATE: Allergan, Inc. (NYSE: AGN) says Darpin data does not support Phase 3 trials. (halted on breaker)

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!